Alcohol, cigarette smoking, dietary factors and the risk of colorectal adenomas and hyperplastic polyps – a case control study

J. Erhardt,H. Kreichgauer,C. Meisner,J. C. Bode,C. Bode

DOI: https://doi.org/10.1007/S003940200004

IF: 4.8646

2002-02-01

European Journal of Nutrition

Abstract:

What problem does this paper attempt to address?

Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques

Lulu Huang,Tongyi Zhao,Weijun Zhao,Andong Shao,Huajun Zhao,Wenxuan Ma,Yingfei Gong,Xianhuan Zeng,Changzhen Weng,Lingling Bu,Zhenhua Di,Shiyu Sun,Qinsheng Dai,Minhui Sun,Limei Wang,Zhenguang Liu,Leilei Shi,Jiesen Hu,Shentong Fang,Cheng Zhang,Jian Zhang,Guan Wang,Karin Loré,Yong Yang,Ang Lin

DOI: https://doi.org/10.1080/22221751.2024.2309985

2024-02-13

Emerging Microbes & Infections

Abstract:Herpes zoster remains an important global health issue and mainly occurs in aged and immunocompromised individuals with an early exposure history to Varicella Zoster Virus (VZV). Although the licensed vaccine Shingrix has remarkably high efficacy, undesired reactogenicity and increasing global demand causing vaccine shortage urged the development of improved or novel VZV vaccines. In this study, we developed a novel VZV mRNA vaccine candidate (named as ZOSAL) containing sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated in an ionizable lipid nanoparticle. In mice and rhesus macaques, ZOSAL demonstrated superior immunogenicity and safety in multiple aspects over Shingrix, especially in the induction of strong T-cell immunity. Transcriptomic analysis revealed that both ZOSAL and Shingrix could robustly activate innate immune compartments, especially Type-I IFN signalling and antigen processing/presentation. Multivariate correlation analysis further identified several early factors of innate compartments that can predict the magnitude of T-cell responses, which further increased our understanding of the mode of action of two different VZV vaccine modalities. Collectively, our data demonstrated the superiority of VZV mRNA vaccine over licensed subunit vaccine. The mRNA platform therefore holds prospects for further investigations in next-generation VZV vaccine development.

immunology,infectious diseases,microbiology
Getting to zero: male circumcision for HIV prevention in The Bahamas.

C. George,D. Brennen,R. Roberts,A. Rabie,S. Read

DOI: https://doi.org/10.7727/WIMJ.2012.263

2012-12-01

West Indian Medical Journal

Abstract:INTRODUCTION The American Academy of Pediatrics has recently released a policy statement in support of male circumcision (MC) for newborns in the United States of America [USA] (1). In order to gather information on MC in The Bahamas, our research team from The Bahamas and Canada will soon be launching a two-year study which will measure the prevalence of MC in adults. It will assess healthcare providers’ attitudes toward circumcision, and societal knowledge and attitudes about this practice. We believe that this may set the stage for further work on the reduction of the burden of HIV in The Bahamas and other countries in the region. The Bahamas has seen important gains in the management of its HIV epidemic but the prevalence still remains high and is estimated to be 3% (2). Since 1994, AIDS has remained the leading cause of death in the 15–49-year age group in The Bahamas. The epidemic has been characterized as a heterosexual epidemic with a reported female to male ratio of 0.83:1 (2).
Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice

Han Cao,Yunfei Wang,Ning Luan,Cunbao Liu

DOI: https://doi.org/10.3390/vaccines9040310

2021-03-25

Vaccines

Abstract:Theoretically, the subunit herpes zoster vaccine ShingrixTM could be used as a varicella vaccine that avoids the risk of developing shingles from vaccination, but bedside mixing strategies and the limited supply of the adjuvant component QS21 have made its application economically impracticable. With lipid nanoparticles (LNPs) that were approved by the FDA as vectors for severe acute respiratory syndrome coronavirus 2 vaccines, we designed a series of vaccines efficiently encapsulated with varicella-zoster virus glycoprotein E (VZV-gE) and nucleic acids including polyinosinic-polycytidylic acid (Poly I:C) and the natural phosphodiester CpG oligodeoxynucleotide (CpG ODN), which was approved by the FDA as an immunostimulator in a hepatitis B vaccine. Preclinical trial in mice showed that these LNP vaccines could induce VZV-gE IgG titers more than 16 times those induced by an alum adjuvant, and immunized serum could block in vitro infection completely at a dilution of 1:80, which indicated potential as a varicella vaccine. The magnitude of the cell-mediated immunity induced was generally more than 10 times that induced by the alum adjuvant, indicating potential as a zoster vaccine. These results showed that immunostimulatory nucleic acids together with LNPs have promise as safe and economical varicella and zoster vaccine candidates.

immunology,medicine, research & experimental
Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice

Yunfei Wang,Jialong Qi,Han Cao,Cunbao Liu

DOI: https://doi.org/10.1007/s12250-020-00261-y

Abstract:The subunit herpes zoster vaccine Shingrix is superior to attenuated vaccine Zostavax in both safety and efficacy, yet its unlyophilizable liposome delivery system and the limited supply of naturally sourced immunological adjuvant QS-21 still need to be improved. Based on poly(lactic-co-glycolic acid) (PLGA) delivery systems that are stable during the lyophilization and rehydration process and using a double-emulsion (w/o/w) solvent evaporation method, we designed a series of nanoparticles with varicella-zoster virus antigen glycoprotein E (VZV-gE) as an antigen and nucleic acids including polyinosinic-polycytidylic acid (Poly I:C) and phosphodiester CpG oligodeoxynucleotide (CpG ODN), encapsulated as immune stimulators. While cationic lipids (DOTAP) have more potential than neutral lipids (DOPC) for activating gE-specific cell-mediated immunity (CMI) in immunized mice, especially when gE is encapsulated in and presented on the surface of nanoparticles, PLGA particles without lipids have the greatest potential to induce not only the highest gE-specific IgG titers but also the strongest gE-specific CMI responses, including the highest proportions of interferon-γ (IFN-γ)- and interleukin-2 (IL-2)-producing CD4+/CD8+ T cells according to a flow cytometry assay and the greatest numbers of IFN-γ- and IL-2-producing splenocytes according to an enzyme-linked immunospot (ELISPOT) assay. These results showed that immune-stimulating nucleic acids together with the PLGA delivery system showed promise as a safe and economical varicella and zoster vaccine candidate.
Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice

Dongdong Li,Lijun Bian,Lili Cui,Jingying Zhou,Gaotian Li,Xiaoyan Zhao,Liao Xing,Jiaxing Cui,Bo Sun,Chunlai Jiang,Wei Kong,Yong Zhang,Yan Chen

DOI: https://doi.org/10.2147/IJN.S464720

2024-08-06

Abstract:Purpose: Heterologous immunization using different vaccine platforms has been demonstrated as an efficient strategy to enhance antigen-specific immune responses. In this study, we performed a head-to-head comparison of both humoral and cellular immune response induced by different prime-boost immunization regimens of mRNA vaccine and adjuvanted protein subunit vaccine against varicella-zoster virus (VZV) in middle-aged mice, aiming to get a better understanding of the influence of vaccination schedule on immune response. Methods: VZV glycoprotein (gE) mRNA was synthesized and encapsulated into SM-102-based lipid nanoparticles (LNPs). VZV-primed middle-aged C57BL/6 mice were then subjected to homologous and heterologous prime-boost immunization strategies using VZV gE mRNA vaccine (RNA-gE) and protein subunit vaccine (PS-gE). The antigen-specific antibodies were evaluated using enzyme-linked immunosorbent assay (ELISA) analysis. Additionally, cell-mediated immunity (CMI) was detected using ELISPOT assay and flow cytometry. Besides, in vivo safety profiles were also evaluated and compared. Results: The mRNA-loaded lipid nanoparticles had a hydrodynamic diameter of approximately 130 nm and a polydispersity index of 0.156. Total IgG antibody levels exhibited no significant differences among different immunization strategies. However, mice received 2×RNA-gE or RNA-gE>PS-gE showed a lower IgG1/IgG2c ratio than those received 2×PS-gE and PS-gE> RNA-gE. The CMI response induced by 2×RNA-gE or RNA-gE>PS-gE was significantly stronger than that induced by 2×PS-gE and PS-gE> RNA-gE. The safety evaluation indicated that both mRNA vaccine and protein vaccine induced a transient body weight loss in mice. Furthermore, the protein vaccine produced a notable inflammatory response at the injection sites, while the mRNA vaccine showed no observable inflammation. Conclusion: The heterologous prime-boost strategy has demonstrated that an mRNA-primed immunization regimen can induce a better cell-mediated immune response than a protein subunit-primed regimen in middle-aged mice. These findings provide valuable insights into the design and optimization of VZV vaccines with the potentials to broaden varicella vaccination strategies in the future.
Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine

Anannya Bhattacharya,Lonzaric Jan,Olga Burlak,Jilong Li,Ghanshyam Upadhyay,Katherine Williams,Jinhui Dong,Harrison Rohrer,Michelle Pynn,Andrew Simon,Nathan Kuhlmann,Sergei Pustylnikov,Mariane B. Melo,Antu K. Dey

DOI: https://doi.org/10.1038/s41541-024-00865-5

2024-04-05

npj Vaccines

Abstract:Varicella zoster virus (VZV) is a highly contagious human herpes virus responsible for causing chickenpox (varicella) and shingles (herpes zoster). Despite the approval of a highly effective vaccine, Shingrix ® , the global incidence of herpes zoster is increasing and the economic burden to the health care system and society are substantial due to significant loss of productivity and health complications, particularly among elderly and immunocompromised individuals. This is primarily because access to the vaccines remains mostly limited to countries within developed economies, such as USA and Canada. Therefore, similarly effective vaccines against VZV that are more accessible to the rest-of-the-world are necessary. In this study, we aimed to evaluate immunogenicity and memory response induced by three mRNA-LNP-based vaccine candidates targeting VZV's surface glycoprotein E (gE). C57BL/6 mice were immunized with each candidate vaccine, and humoral and cellular immune responses were assessed. Our results demonstrate that the mRNA-LNP-based vaccine candidates elicited robust and durable humoral responses specific to the gE antigen. Notably, mice vaccinated with the mRNA-LNP vaccines exhibited significantly higher antigen-specific T-cell cytokine production compared to the group receiving Shingrix ® , the current standard of care vaccine. Additionally, mRNA-LNP vaccines induced long-lasting memory response, as evidenced by detection of persistent gE-specific Long-Lived Plasma Cells (LLPCs) and memory T cells four months after final immunization. These findings underscore the potential of our mRNA-LNP-based vaccine candidates in generating potent immune responses against VZV, offering promising prospects for their clinical development as an effective prophylactic vaccine against herpes zoster.

immunology,medicine, research & experimental
Glycoprotein E-Displaying Nanoparticles Induce Robust Neutralizing Antibodies and T-Cell Response against Varicella Zoster Virus

Hong Wang,Sibo Zhang,Wenhui Xue,Yarong Zeng,Liqin Liu,Lingyan Cui,Hongjing Liu,Yuyun Zhang,Lin Chen,Meifeng Nie,Rongwei Zhang,Zhenqin Chen,Congming Hong,Qingbing Zheng,Tong Cheng,Ying Gu,Tingting Li,Ningshao Xia,Shaowei Li

DOI: https://doi.org/10.3390/ijms25189872

IF: 5.6

2024-09-13

International Journal of Molecular Sciences

Abstract:The Varicella zoster virus (VZV), responsible for both varicella (chickenpox) and herpes zoster (shingles), presents significant global health challenges. While primary VZV infection primarily affects children, leading to chickenpox, reactivation in later life can result in herpes zoster and associated post-herpetic neuralgia, among other complications. Vaccination remains the most effective strategy for VZV prevention, with current vaccines largely based on the attenuated vOka strains. Although these vaccines are generally effective, they can induce varicella-like rashes and have sparked concerns regarding cell virulence. As a safer alternative, subunit vaccines circumvent these issues. In this study, we developed a nanoparticle-based vaccine displaying the glycoprotein E (gE) on ferritin particles using the SpyCatcher/SpyTag system, termed FR-gE. This FR-gE nanoparticle antigen elicited substantial gE-specific binding and VZV-neutralizing antibody responses in BALB/c and C57BL/6 mice—responses that were up to 3.2-fold greater than those elicited by the subunit gE while formulated with FH002C, aluminum hydroxide, or a liposome-based XUA01 adjuvant. Antibody subclass analysis revealed that FR-gE produced comparable levels of IgG1 and significantly higher levels of IgG2a compared to subunit gE, indicating a Th1-biased immune response. Notably, XUA01-adjuvanted FR-gE induced a significant increase in neutralizing antibody response compared to the live attenuated varicella vaccine and recombinant vaccine, Shingrix. Furthermore, ELISPOT assays demonstrated that immunization with FR-gE/XUA01 generated IFN-γ and IL-2 levels comparable to those induced by Shingrix. These findings underscore the potential of FR-gE as a promising immunogen for the development of varicella and herpes zoster vaccines.

biochemistry & molecular biology,chemistry, multidisciplinary
Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design

Tingting Chen,Jie Sun,Sibo Zhang,Tingting Li,Liqin Liu,Wenhui Xue,Lizhi Zhou,Siting Liang,Zhili Yu,Qingbing Zheng,Hai Yu,Tong Cheng,Jun Zhang,Ying Gu,Shaowei Li,Ningshao Xia

DOI: https://doi.org/10.1007/s11427-022-2264-1

Abstract:Varicella-zoster virus (VZV) is a highly infectious agent responsible for both varicella and herpes zoster disease. Despite high efficacy, there remain safety and accessibility concerns with the licensed vaccines. Here, we sought to produce a VZV gE immunogen using an E. coli expression system. We found that the soluble expression and yield of gE protein could be enhanced via C-terminal truncations to the protein, thereby facilitating a robust and scalable purification process for the purpose of vaccine manufacturing. The lead truncated gE (aa 31-358), hereafter referred to as tgE, was a homogenous monomer in solution and showed excellent antigenicity. Finally, we assessed and compared the immunogenicity of tgE with commercial vOka LAV and Shingrix vaccine. We found that aluminum-adjuvanted tgE was immunogenic as compared with vOka LAV. When adjuvanted with AS01B, a two-dose immunization of tgE showed comparable or better potency in antibody responses and cell-mediated immunity with those of the Shingrix vaccine at the same dosage, especially in terms of the proportion of IFN-γ-expressing CD4+ T cells. In conclusion, this method of E. coli-mediate tgE expression offers a cost-effective and scalable strategy to generate an ideal VZV gE immunogen for the development of both varicella and zoster vaccines.
Evolution of Some Biochemical Characteristics of the Intestinal Mucosa During the First Postnatal Weeks in C57 Mice. Effects of Thyroxine and Putrescine

A. Etienne-Poncin,G. Dandrifosse,P. Forget,A. Lepoint

DOI: https://doi.org/10.1097/00005176-198910000-00019

1989-10-01

Abstract:In C57 mice, during the third week after birth, there is a rapid conversion of the intestinal epithelium from fetal to mature adult status. Some characteristics (lactase, maltase, diamine oxidase, and sucrase activity; putrescine, spermine and spermidine concentrations; mitotic index) have been analyzed for the proximal, middle, and distal parts of the intestine in mice of different ages: 8, 15, 19, and 60 days. The most important observations recorded were as follows: (a) sucrase- and maltase-specific activities as well as spermine and spermidine contents increased abruptly on the 19th postnatal day and then decreased; (b) decrease of lactase and diamine oxidase-specific activity was recorded between the 15th and 19th postnatal days, (c) later, diamine oxidase-specific activity increased, whereas putrescine content decreased in the proximal part of the intestine; and (d) mitotic index was not significantly different when estimated for the crypts on days 11 and 19. No similar variations of these biochemical parameters were observed over a period of 3 days when mice were injected with thyroxine on the 8th day or when mice received putrescine per os on the 9th day, as explained in the text. Only a slight but significant variation in sucrase- or maltase-specific activity with thyroxine and a variation of the lactase or DAO-specific activity of the distal part of the intestine with putrescine were recorded.
A Synergistic Lipid Nanoparticle Encapsulating Mrna Shingles Vaccine Induces Potent Immune Responses and Protects Guinea Pigs from Viral Challenges

Xingdi Cheng,Sujia Liu,Jing Sun,Lin Liu,Xinghuan Ma,Jingjiao Li,Bangda Fan,Chen Yang,Yuanyuan Zhao,Shuai Liu,Yixing Wen,Wei Li,Simin Sun,Shiwei Mi,Haonan Huo,Lei Miao,Hao Pan,Xiaolan Cui,Jiaqi Lin,Xueguang Lu

DOI: https://doi.org/10.1002/adma.202310886

IF: 29.4

2023-12-26

Advanced Materials

Abstract:Shingles is caused by the reactivation of varicella zoster virus (VZV) and manifests as painful skin rashes. While the recombinant protein‐based vaccine has proven highly effective, it encounters supply chain challenges due to a shortage of the necessary adjuvant. Messenger RNA (mRNA)‐based vaccines can be rapidly produced on a large scale, but their effectiveness relies on efficient delivery and sequence design. Here, we have developed an mRNA‐based VZV vaccine using a synergistic lipid nanoparticle (Syn‐LNP) containing two different ionizable lipids. Syn‐LNP showed superior mRNA expression compared to LNPs formulated with either type of ionizable lipid and to a commercialized LNP. After encapsulating VZV glycoprotein E (gE)‐encoding mRNA, mgE@Syn‐LNP induced robust humoral and cellular immune responses in two strains of mice. The magnitude of these responses is similar to that induced by adjuvanted recombinant gE proteins and significantly higher than that observed with live‐attenuated VZV. mgE@Syn‐LNP exhibits durable humoral responses for over seven months without obvious adverse effects. In addition, mgE@Syn‐LNP protects vaccinated guinea pigs against live VZV challenges. Preliminary studies on the mRNA antigen design revealed that the removal of glycosylation sites of gE greatly reduced its immune responses. Collectively, Syn‐LNP encapsulating gE‐encoded mRNA holds great promise as a shingles vaccine. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

Huiling Xu,Yanli Wang,Guangwei Han,Weihuan Fang,Fang He

DOI: https://doi.org/10.21203/rs.2.18234/v1

2019-01-01

Abstract:Background: Outbreaks of CSFV cause significant economic losses in the swine industry. Subunit vaccines present advantages in DIVA immunogenicity and safety. The technology was limited due to the low yield and the high cost with multiple and large doses. Results: A novel E2 sequence (E2ZJ) was identified from an epidemic strain of Zhejiang for outstanding secretion in baculovirus and enhanced immunogenicity. E2 secretion induced with the selected signal peptide, SPZJ, increase at least 50% as compared to any other signal peptides tested. Besides, unique antigenic features were identified in E2ZJ. E2ZJ elicited CSFV antibody at the earlier stage than other E2 types tested in mice. Meantime, higher level of neutralization antibody with E2ZJ was detected than other E2s at the same dosage. Further, in piglets, E2ZJ successfully elicited neutralizing immunity. A single dose of 5 μg of E2ZJ was sufficient to induce protective antibody against CSFV in piglets and provided 100% protection against lethal virus challenge. Conclusions: In this study, with advantages in secretion and immunogenicity over counterparts, SPZJ-E2ZJ is a cost-effective and efficacious vaccine candidate against CSFV. Keywords: Classical swine fever virus; novel signal peptide; SPZJ-E2ZJ; subunit vaccine; protective immunity
Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant

Su Jeen Lee,Hyo‐Jung Park,Hae Li Ko,Jung Eun Lee,Hyun Joo Lee,Hun Kim,Jae‐Hwan Nam

DOI: https://doi.org/10.1002/iid3.297

2020-03-13

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Varicella‐zoster virus (VZV), a human alphaherpesvirus 3, elicits both chickenpox and shingles and/or postherpetic neuralgia. A live attenuated vaccine (LAV) and glycoprotein E (gE) subunit vaccine were developed to prevent VZV‐induced diseases. We recently reported that single‐strand RNA (ssRNA) based on the intergenic region of the internal ribosome entry site of cricket paralysis virus (CrPV) is an effective adjuvant for protein‐based and virus‐like particle‐based vaccines. Here, Chinese hamster ovary expression system and an LAV from Oka/SK strains.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We appraised the adjuvant effect of the same CrPV ssRNA encoding the gE gene formulated in the two vaccines using VZV‐primed C57BL/6 mice and guinea pigs. Humoral immunity and cell‐mediated immunity were assessed by enzyme‐linked immunosorbent assay (ELISA) and ELISPOT in gE subunit vaccine and by ELISA and fluorescent antibody to membrane antigen in LAV.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The gE subunit vaccine‐induced gE‐specific antibodies and CD4<sup>+</sup> T‐cell responses (indicated by interferon‐γ [IFN‐γ] and interleukin‐2 secretion) in the ssRNA‐based adjuvant containing the VZV gE gene. Therefore, an ssRNA adjuvant combined with gE antigen can trigger the innate immune response and induce an adaptive immune response to ultimately activate humoral and cell‐mediated responses. VZV LAV could also induce VZV‐specific antibodies and IFN‐γ stimulated by LAV, whereas the effect of ssRNA as a vaccine adjuvant could not be confirmed. However, the ssRNA adjuvant increased VZV‐specific neutralizing antibody response. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Taken together, these results highlight that the gE subunit vaccine and LAV developed in this study can be functional VZV vaccines, and ssRNAs appear to function better as adjuvants in a subunit vaccine than in an LAV.</p></section>

immunology
Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Lidao Bao,Guomin Wei,Hongmei Gan,Xianhua Ren,Ruilian Ma,Y I Wang,Haijun Lv

DOI: https://doi.org/10.3892/etm.2016.3086

Abstract:In the present study a eukaryotic expression vector of varicella zoster virus (VZV) glycoprotein E (gE) was constructed and enabled to express in COS7 cells. Furthermore, a specific immune response against the VZV gE eukaryotic expression plasmid was induced in BALB/c mice. The VZV gE gene was amplified using polymerase chain reaction (PCR) and cloned into a eukaryotic expression vector, pcDNA3.1. The recombinant vector was subsequently transfected into COS7 cells using a liposome transfection reagent. The recombinant protein was instantaneously expressed by the transfected cells, as detected by immunohistochemistry, and the recombinant pcDNA-VZV gE plasmid was subsequently used to immunize mice. Tissue expression levels were analyzed by reverse transcription-PCR. In addition, the levels of serum antibodies and spleen lymphocyte proliferation activity were investigated. The amplified target gene included the full-length gE gene (~2.7 kb), and the recombinant expression vector induced gE expression in COS7 cells. In addition, the expression plasmid induced sustained expression in vivo following immunization of mice. Furthermore, the plasmid was capable of inducing specific antibody production and effectively stimulating T cell proliferation. Effective humoral and cellular immunity was triggered in the mice immunized with the VZV gE eukaryotic expression vector. The results of the present study laid the foundation for future research into a VZV DNA vaccine.
Study on Ductility of Ti Aluminides Using Mamdani Fuzzy Inference System

R. Gupta,B. Pant,P. P. Sinha,R. Mehta,V. Agarwala

DOI: https://doi.org/10.1007/978-81-322-0487-9_2

Abstract:
Dendritic cell targeting virus-like particle delivers mRNA for in vivo immunization

Di Yin,Sikai Ling,Xiaolong Tian,Yang Li,Zhijue Xu,Hewei Jiang,Xue Zhang,Xiaoyuan Wang,Yi Shi,Quanjun Wang,Jianjiang Xu,Wei Hong,Heng Xue,hang yang,Yan Zhang,Lintai Da,Ze-Guang Han,Sheng-ce Tao,Jiaxu Hong,Tianlei Ying,Yujia Cai

DOI: https://doi.org/10.21203/rs.3.rs-1096471/v1

2021-01-01

Abstract:mRNA vaccine was approved clinically in 2020. Future development includes delivering mRNA to dendritic cells (DCs) specifically to improve effectiveness and avoid off-target cytotoxicity. Here, we developed virus-like particles (VLPs) as a DC tropic mRNA vaccine vector and showed the prophylactic effects in both SARS-CoV-2 and HSV-1 infection models. The VLP mRNA vaccine elicited strong cytotoxic T cell immunity and durable antibody response with the spike-specific antibodies that lasted for more than 9 months. Importantly, we were able to target mRNA to DCs by pseudotyping VLP with engineered Sindbis virus glycoprotein and found the DC-targeting mRNA vaccine significantly enhanced the titer of antigen-specific IgG, protecting the hACE-2 mice from SARS-CoV-2 infection. Additionally, we showed DC-targeted mRNA vaccine also protected mice from HSV-1 infection when co-delivering the gB and gD mRNA. Thus, the VLP may serve as an in situ DC vaccine and accelerate the further development of mRNA vaccines.
Rational development of multicomponent mRNA vaccine candidates against mpox

Rong-Rong Zhang,Zheng-Jian Wang,Yi-Long Zhu,Wei Tang,Chao Zhou,Suo-Qun Zhao,Mei Wu,Tao Ming,Yong-Qiang Deng,Qi Chen,Ning-Yi Jin,Qing Ye,Xiao Li,Cheng-Feng Qin

DOI: https://doi.org/10.1080/22221751.2023.2192815

2023-04-02

Emerging Microbes & Infections

Abstract:The re-emerging mpox (formerly monkeypox) virus (MPXV), a member of Orthopoxvirus genus together with variola virus (VARV) and vaccinia virus (VACV), has led to public health emergency of international concern since July 2022. Inspired by the unprecedent success of coronavirus disease 2019 (COVID-19) mRNA vaccines, the development of a safe and effective mRNA vaccine against MPXV is of high priority. Based on our established lipid nanoparticle (LNP)-encapsulated mRNA vaccine platform, we rationally constructed and prepared a panel of multicomponent MPXV vaccine candidates encoding different combinations of viral antigens including M1R, E8L, A29L, A35R, and B6R. In vitro and in vivo characterization demonstrated that two immunizations of all mRNA vaccine candidates elicit a robust antibody response as well as antigen-specific Th1-biased cellular response in mice. Importantly, the penta- and tetra-component vaccine candidates AR-MPXV5 and AR-MPXV4a showed superior capability of inducing neutralizing antibodies as well as of protecting from VACV challenge in mice. Our study provides critical insights to understand the protection mechanism of MPXV infection and direct evidence supporting further clinical development of these multicomponent mRNA vaccine candidates.

immunology,infectious diseases,microbiology
Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures

Rickard Nordén,Jonas Nilsson,Ebba Samuelsson,Christian Risinger,Carina Sihlbom,Ola Blixt,Göran Larson,Sigvard Olofsson,Tomas Bergström

DOI: https://doi.org/10.3390/ijms20040954

IF: 5.6

2019-02-22

International Journal of Molecular Sciences

Abstract:A recombinant subunit vaccine (Shingrix®) was recently licensed for use against herpes zoster. This vaccine is based on glycoprotein E (gE) of varicella zoster virus (VZV), the most abundantly expressed protein of VZV, harboring sites for N- and O-linked glycosylation. The subunit vaccine elicits stronger virus-specific CD4+ T cell response as well as antibody B cell response to gE, compared to the currently used live attenuated vaccine (Zostavax®). This situation is at variance with the current notion since a live vaccine, causing an active virus infection, should be far more efficient than a subunit vaccine based on only one single viral glycoprotein. We previously found gE to be heavily glycosylated, not least by numerous clustered O-linked glycans, when it was produced in human fibroblasts. However, in contrast to Zostavax®, which is produced in fibroblasts, the recombinant gE of Shingrix® is expressed in Chinese hamster ovary (CHO) cells. Hence, the glycan occupancy and glycan structures of gE may differ considerably between the two vaccine types. Here, we aimed at (i) defining the glycan structures and positions of recombinant gE and (ii) identifying possible features of the recombinant gE O-glycosylation pattern contributing to the vaccine efficacy of Shingrix®. Firstly, recombinant gE produced in CHO cells (“Shingrix situation”) is more scarcely decorated by O-linked glycans than gE from human fibroblasts (“Zostavax situation”), with respect to glycan site occupancy. Secondly, screening of immunodominant B cell epitopes of gE, using a synthetic peptide library against serum samples from VZV-seropositive individuals, revealed that the O-linked glycan signature promoted binding of IgG antibodies via a decreased number of interfering O-linked glycans, but also via specific O-linked glycans enhancing antibody binding. These findings may, in part, explain the higher protective efficacy of Shingrix®, and can also be of relevance for development of subunit vaccines to other enveloped viruses.

biochemistry & molecular biology,chemistry, multidisciplinary
Prokaryotic Expression and Priliminary Evaluation of the Immunization Efficacy of Varicella-Zoster Virus Glycoprotein E

Gao Yan,Chen Qi,Ren Meng,Chen Hong,Yue Wentao

DOI: https://doi.org/10.3760/cma.j.issn.1673-4092.2019.02.010

2019-01-01

International Journal of Virology

Abstract:Objective To express extracellular domain ofvaricella-zoster virus (VZV) glycoprotein E (gE) in Escherichia coli and to evaluate its immunization efficacy.Methods The extracellular domain of VZV gE was codon optimized and cloned into the prokaryotic expression vector pET-48b.After sequencing identification,the vector was transformed into competent cell BL21 (DE3).Isopropyl β-D-thiogalactoside (IPTG) was used to induce the expression in E.coli.SDS-PAGE electrophoresis and western blot (WB) were used to identify the specificity.The target protein was purified and renatured by Ni2+-NTA column and was used to immunize Balb/c mice.ELISA was used to detect the specificity and titer of serum.Results The extracellular domain of VZV gE was successfully expressed as inclusion bodies,and the purity was about 90％ after purification and renaturation.WB indicated that VZV gE had good immunoreactivity.After immunizing mice,specific antibodies can be produced at the same level as the commercial live attenuated varicella vaccine.Conclusions The VZV gE protein was expressed in prokaryotic expression system successfully and its ability of inducing specific immune responses was confirmed.The study provides scientific basis for the development of VZV vaccine.
Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies

Wayne D. Harshbarger,Genevieve Holzapfel,Nishat Seraj,Sai Tian,Chelsy Chesterman,Zongming Fu,Yan Pan,Claire Harelson,Dongjun Peng,Ying Huang,Sumana Chandramouli,Enrico Malito,Matthew James Bottomley,James Williams

DOI: https://doi.org/10.3390/vaccines12101111

2024-09-28

Vaccines

Abstract:Background: Varicella zoster virus (VZV) is the causative agent for chickenpox and herpes zoster (HZ, shingles). HZ is a debilitating disease affecting elderly and immunocompromised populations. Glycoprotein E (gE) is indispensable for viral replication and cell-to-cell spread and is the primary target for anti-VZV antibodies. Importantly, gE is the sole antigen in Shingrix, a highly efficacious, AS01B-adjuvanted vaccine approved in multiple countries for the prevention of HZ, yet the three-dimensional (3D) structure of gE remains elusive. Objectives: We sought to determine the structure of VZV gE and to understand in detail its interactions with neutralizing antibodies. Methods: We used X-ray crystallography and cryo-electron microscopy to elucidate structures of gE bound by recombinant Fabs of antibodies previously elicited through vaccination with Zostavax, a live, attenuated vaccine. Results: The 3D structures resolve distinct central and C-terminal antigenic domains, presenting an array of diverse conformational epitopes. The central domain has two beta-sheets and two alpha helices, including an IgG-like fold. The C-terminal domain exhibits 3 beta-sheets and an Ig-like fold and high structural similarity to HSV1 gE. Conclusions: gE from VZV-infected cells elicits a human antibody response with a preference for the gI binding domain of gE. These results yield insights to VZV gE structure and immunogenicity, provide a framework for future studies, and may guide the design of additional herpesvirus vaccine antigens. Teaser: Structures of varicella zoster virus glycoprotein E reveal distinct antigenic domains and define epitopes for vaccine-elicited human antibodies.

immunology,medicine, research & experimental

Alcohol, cigarette smoking, dietary factors and the risk of colorectal adenomas and hyperplastic polyps – a case control study

Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques

Getting to zero: male circumcision for HIV prevention in The Bahamas.

Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice

Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice

Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice

Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine

Glycoprotein E-Displaying Nanoparticles Induce Robust Neutralizing Antibodies and T-Cell Response against Varicella Zoster Virus

Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design

Evolution of Some Biochemical Characteristics of the Intestinal Mucosa During the First Postnatal Weeks in C57 Mice. Effects of Thyroxine and Putrescine

A Synergistic Lipid Nanoparticle Encapsulating Mrna Shingles Vaccine Induces Potent Immune Responses and Protects Guinea Pigs from Viral Challenges

Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant

Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Study on Ductility of Ti Aluminides Using Mamdani Fuzzy Inference System

Dendritic cell targeting virus-like particle delivers mRNA for in vivo immunization

Rational development of multicomponent mRNA vaccine candidates against mpox

Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures

Prokaryotic Expression and Priliminary Evaluation of the Immunization Efficacy of Varicella-Zoster Virus Glycoprotein E

Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies